OBJECTIVE: Insulin-like growth factor (IGF) I stimulates the proliferation of hepatic stellate cells (HSC), the primary source of extracellular matrix accumulation in liver fibrosis. In contrast, insulin-like growth factor binding protein (IGFBP) 3, the most abundant IGFBP in circulation, negatively modulates HSC mitogenesis. To investigate the role of the IGF axis in hepatitis C virus (HCV)-related liver disease among high-risk patients, we prospectively evaluated HCV-viremic/HIV-positive women. DESIGN: A cohort investigation. METHODS: Total IGF-I and IGFBP-3 were measured in baseline serum specimens obtained from 472 HCV-viremic/HIV-positive subjects enrolled in the Women's Interagency HIV Study, a large multi-institutional cohort. The aspartate aminotransferase to platelet ratio index (APRI), a marker of liver fibrosis, was assessed annually. RESULTS: Normal APRI levels (< 1.0) at baseline were detected in 374 of the 472 HCV-viremic/HIV-positive subjects tested, of whom 302 had complete liver function test data and were studied. IGF-I was positively associated [adjusted odds ratio comparing the highest and lowest quartiles (AORq4-q1), 5.83; 95% confidence interval (CI) 1.17-29.1; Ptrend = 0.03], and IGFBP-3 was inversely associated (AORq4-q1, 0.13; 95% CI 0.02-0.76; Ptrend = 0.04), with subsequent (incident) detection of an elevated APRI level (> 1.5), after adjustment for the CD4 T-cell count, alcohol consumption, and other risk factors. CONCLUSION: High IGF-I may be associated with increased risk and high IGFBP-3 with reduced risk of liver disease among HCV-viremic/HIV-positive women.
OBJECTIVE:Insulin-like growth factor (IGF) I stimulates the proliferation of hepatic stellate cells (HSC), the primary source of extracellular matrix accumulation in liver fibrosis. In contrast, insulin-like growth factor binding protein (IGFBP) 3, the most abundant IGFBP in circulation, negatively modulates HSC mitogenesis. To investigate the role of the IGF axis in hepatitis C virus (HCV)-related liver disease among high-risk patients, we prospectively evaluated HCV-viremic/HIV-positive women. DESIGN: A cohort investigation. METHODS: Total IGF-I and IGFBP-3 were measured in baseline serum specimens obtained from 472 HCV-viremic/HIV-positive subjects enrolled in the Women's Interagency HIV Study, a large multi-institutional cohort. The aspartate aminotransferase to platelet ratio index (APRI), a marker of liver fibrosis, was assessed annually. RESULTS: Normal APRI levels (< 1.0) at baseline were detected in 374 of the 472 HCV-viremic/HIV-positive subjects tested, of whom 302 had complete liver function test data and were studied. IGF-I was positively associated [adjusted odds ratio comparing the highest and lowest quartiles (AORq4-q1), 5.83; 95% confidence interval (CI) 1.17-29.1; Ptrend = 0.03], and IGFBP-3 was inversely associated (AORq4-q1, 0.13; 95% CI 0.02-0.76; Ptrend = 0.04), with subsequent (incident) detection of an elevated APRI level (> 1.5), after adjustment for the CD4 T-cell count, alcohol consumption, and other risk factors. CONCLUSION: High IGF-I may be associated with increased risk and high IGFBP-3 with reduced risk of liver disease among HCV-viremic/HIV-positive women.
Authors: J Macías; J A Girón-González; M González-Serrano; D Merino; P Cano; J A Mira; A Arizcorreta-Yarza; J Ruíz-Morales; J M Lomas-Cabeza; J A García-García; J E Corzo; J A Pineda Journal: Gut Date: 2005-08-23 Impact factor: 23.059
Authors: S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman Journal: Epidemiology Date: 1998-03 Impact factor: 4.822
Authors: Andrew G Renehan; Marcel Zwahlen; Christoph Minder; Sarah T O'Dwyer; Stephen M Shalet; Matthias Egger Journal: Lancet Date: 2004-04-24 Impact factor: 79.321
Authors: Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle Journal: Gastroenterology Date: 2003-01 Impact factor: 22.682
Authors: G Svegliati-Baroni; F Ridolfi; A Di Sario; A Casini; L Marucci; G Gaggiotti; P Orlandoni; G Macarri; L Perego; A Benedetti; F Folli Journal: Hepatology Date: 1999-06 Impact factor: 17.425
Authors: Marshall J Glesby; Donald R Hoover; Qiuhu Shi; Ann Danoff; Andrea Howard; Phyllis Tien; Dan Merenstein; Mardge Cohen; Elizabeth Golub; Jack Dehovitz; Marek Nowicki; Kathryn Anastos Journal: Antivir Ther Date: 2010
Authors: Marshall J Glesby; Donald R Hoover; Farbod Raiszadeh; Irene Lee; Qiuhu Shi; Ginger Milne; Stephanie C Sanchez; Wei Gao; Robert C Kaplan; Jason D Morrow; Kathryn Anastos Journal: Antivir Ther Date: 2009